各種尿路性器癌における化学療法後の顆粒球減少症に対するCSF-HU(ヒト尿由来コロニー刺激因子:P-100)の臨床使用成績

Abstract

術前後の化学療法により, 白血球数が2000/mm3以下に減少した者の内performance status 0～3の42例に対して, 本剤800万単位を1日1回7日間点滴静注し検討した.1)白血球数, 顆粒球数の変動を総合評価した主治医による有用率は52.4%, また薬効判定委員会による有効率は50.0%であった.2)癌種別, 使用化学療法剤別でみた有用率, 有効率には一定の傾向は認められなかった.3)非投与期と比較し, P-100投与により顆粒球数, 白血球数の低下が有意に抑制され, 回復の日数も短縮する傾向が認められた.4)副作用としては2.3%に軽度の一過性発熱が認められたのみであった

We examined the value of the CSF-HU preparation (colony-stimulating factor derived from human urine: P-100) to prevent or treat granulocytopenia induced by anticancer chemotherapy. Subjects were urogenital cancer patients who underwent two courses of the same chemotherapy regimen. Among these patients, we selected the subjects whose leucocyte counts were decreased to less than 2000/mm3 after the first course of anticancer chemotherapy. P-100 was administered from the following day of the end of the second course of chemotherapy at a dose of 8, 000, 000 units/day by intravenous drip infusion for 7 successive days. According to the global evaluation by consideration of changes in leucocyte and granulocyte counts, the utility rate by physicians was 52.4% (22/42), and that by a committee was 50.0% (18/36). No difference was seen in utility rate and efficacy rate according to P.S., cancer types and antineoplastic drugs used. Side effects were noted only in 2.3% (1/44) which was mild and transient fever. These findings suggest that P-100 is a very useful drug for prevention and/or treatment of granulocytopenia following cancer chemotherapy.